Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C41H64F2O7 |
| Molecular Weight | 706.9395 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(O[C@H](CCC)O2)C(=O)COC(=O)CCCCCCCCCCCCCCC
InChI
InChIKey=IRCYEVZQEUIZIW-NEESCNQASA-N
InChI=1S/C41H64F2O7/c1-5-7-8-9-10-11-12-13-14-15-16-17-18-20-36(47)48-27-34(46)41-35(49-37(50-41)19-6-2)25-29-30-24-32(42)31-23-28(44)21-22-38(31,3)40(30,43)33(45)26-39(29,41)4/h23,29-30,32-33,35,37,45H,5-22,24-27H2,1-4H3/t29-,30-,32-,33-,35+,37+,38-,39-,40-,41+/m0/s1
Rofleponide is a third generation synthetic glucocorticosteroid. This compound has high affinity for the rat thymus glucocorticoid receptor and showed a very high biotransformation rate in the human liver. Rofleponide was being investigated for its anti-inflammatory, immunosuppressive and anti-anaphylactic activity. It was evaluated in phase II clinical trials for its safety and efficacy in allergic rhinitis and asthma, and in a preclinical study for use in inflammatory bowel disease, but development of this drug was discontinued. Rofleponide was never marketed.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
144653-57-6
Created by
admin on Sat Dec 16 20:10:31 GMT 2023 , Edited by admin on Sat Dec 16 20:10:31 GMT 2023
|
PRIMARY | |||
|
9833541
Created by
admin on Sat Dec 16 20:10:31 GMT 2023 , Edited by admin on Sat Dec 16 20:10:31 GMT 2023
|
PRIMARY | |||
|
8KB3J5M6UG
Created by
admin on Sat Dec 16 20:10:31 GMT 2023 , Edited by admin on Sat Dec 16 20:10:31 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
